Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can laser guidance make lung biopsies safer and more accurate?

NCT ID NCT06741826

Diagnosis Sponsor: China-Japan Friendship Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This trial tests whether using a laser-based imaging tool called confocal laser endomicroscopy (pCLE) to guide lung biopsies improves diagnosis in people with suspected interstitial lung disease. Researchers will compare this approach with the standard method, which uses X-ray guidance. The study includes 430 adults whose diagnosis remains unclear after standard tests, and it measures how often the biopsy leads to a specific diagnosis and whether complications occur.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Probe-based confocal laser endomicroscopy (pCLE) guidance during transbronchial lung cryobiopsy
What this could lead to
If pCLE guidance improves biopsy accuracy, it could lead to more precise diagnoses of interstitial lung disease with fewer complications.
What could go wrong
The trial is at one center and may not reflect broader practice. pCLE adds complexity and might not improve outcomes enough to justify its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

430 people

The number who actually took part.

Started

Dec 2025

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Eligibility Criteria： 1. adults with suspected interstitial lung disease (ILD). 2. Clinical and HRCT findings insufficient to establish a definitive diagnosis. 3. Histopathological evaluation by TBLC considered necessary after multidisciplinary discussion. 4. Age ≥18 years 5. Written informed consent provided. Exclusion Criteria: 1. Contraindications to bronchoscopy or TBLC. 2. Severe hypoxemia or uncontrolled bleeding risk. 3. Severe pulmonary hypertension or unstable cardiopulmonary disease. 4. Active infection. 5. Pregnancy. 6. Inability to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Interstitial lung disease (ILD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

interstitial lung disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Interstitial lung disease (ILD)

Contacts and locations

Locations

  • China-Japan Friendship Hospital

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.